Patents Assigned to Vitreo-Retinal Technologies, Inc.
  • Publication number: 20070105950
    Abstract: Methods for treating disorders of the eye and/or disorders of a nerve in a human or veterinary patient by delivering to the patient a therapeutically effective amount of a compound selected from the group of; urea, urea derivatives, thiourea, thiourea derivatives, guanidine, guanidine derivatives and compounds having General Formula I as set forth herein. For ophthalmic applications, the compound may be delivered by intravitreal injection such that the compound causes vitreal liquefaction, posterior vitreoretinal detachment and other affects.
    Type: Application
    Filed: October 23, 2006
    Publication date: May 10, 2007
    Applicant: Vitreo-Retinal Technologies, Inc.
    Inventors: Vicken Karageozian, David Castillejos, John Park
  • Patent number: 7008960
    Abstract: Methods and preparatons for treating disorders of the eye and/or causing posterior vitreous disconnection or disinsertion. Preparations containing a) urea, b) urea derivatives (e.g., hydroxyurea, thiourea), c) a non-steroidal anti-inflamatory agents, d) antmetabolites, e) urea, urea derivatives, non-enzymatic proteins, nucleosides, nucleotides and their derivatives (e.g., adenine, adenosine, cytosine, cytadine, guanine, guanitadine, guanidinium, thymidine, thimitadine, uradine, uracil, cystine), uric acid, calcium acetal salicylate, ammonium sulfate or other compound capable of causing non-enzymatic dissolution of the hyaloid membrane or e) any of the possible combinations thereof, are administered to the eye in therapeutically effective amounts.
    Type: Grant
    Filed: August 9, 2002
    Date of Patent: March 7, 2006
    Assignee: Vitreo-Retinal Technologies, Inc.
    Inventor: David Castillejos
  • Publication number: 20040043082
    Abstract: Methods and preparations for treating disorders of the eye and/or causing dissolution of corneal proteoglycans and organized healing of corneal stroma, softening of the cornea for non-surgical refractive correction of eyesight, removing corneal haze and opacification, inhibiting fibroblasts and preventing corneal fibrosis and scar formation, treating pterigiums and treating corneal neovascularization as well as iris neovascularization. Preparations containing a) urea, b) urea derivatives (e.g., hydroxyurea, thiourea), c) antimetabolites, e) urea, urea derivatives, non-enzymatic proteins, nucleosides, nucleotides and their derivatives (e.g.
    Type: Application
    Filed: March 14, 2003
    Publication date: March 4, 2004
    Applicant: Vitreo-Retinal Technologies, Inc.
    Inventors: Vicken H. Karageozian, David Castillejos, John Park, Gabriel Arthuro Carpio Aragon, Jose Luis Gutierres Floress
  • Publication number: 20030199574
    Abstract: Methods for treating disorders of the eye and/or disorders of a nerve in a human or veterinary patient by delivering to the patient a therapeutically effective amount of a compound selected from the group of; urea, urea derivatives, thiourea, thiourea derivatives, guanidine, guanidine derivatives and compounds having General Formula I as set forth herein. For ophthalmic applications, the compound may be delivered by intravitreal injection such that the compound causes vitreal liquefaction, posterior vitreoretinal detachment and other affects.
    Type: Application
    Filed: February 13, 2003
    Publication date: October 23, 2003
    Applicant: Vitreo-Retinal Technologies, Inc.
    Inventors: Vicken H. Karageozian, David Castillejos, John Park
  • Patent number: 6462071
    Abstract: Methods and preparations for treating disorders of the eye and/or causing posterior vitreous disconnection or disinsertion. Preparations containing a) urea, b) urea derivatives (e.g., hydroxyurea, thiourea), c) a non-steroidal anti-inflamatory agents, d) antmetabolites, e) urea, urea derivatives, non-enzymatic proteins, nucleosides, nucleotides and their derivatives (e.g., adenine, adenosine, cytosine, cytadine, guanine, guanitadine, guanidinium, thymidine, thimitadine, uradine, uracil, cystine), uric acid, calcium acetal salicylate, ammonium sulfate or other compound capable of causing non-enzymatic dissolution of the hyaloid membrane or e) any of the possible combinations thereof, are administered to the eye in therapeutically effective amounts.
    Type: Grant
    Filed: March 2, 2000
    Date of Patent: October 8, 2002
    Assignee: Vitreo-Retinal Technologies, Inc.
    Inventor: David Castillejos